Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms
Conditions
Brief summary
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
Interventions
DRUGPaclitaxel
Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle
DRUGCarboplatin
Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles
DRUGAtezolizumab
Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
DRUGBevacizumab
Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
Placebo matching to atezolizumab on Day 1 of each 21-day cycle
Sponsors
GOG Foundation
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC), peritoneal primary carcinoma, or fallopian tube cancer * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Life expectancy greater than (\>) 12 weeks * For participants who receive therapeutic anticoagulation: stable anticoagulant regimen * Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in paraffin blocks (preferred) or at least 20 unstained slides (for detailed tissue requirements at screening)
Exclusion criteria
* Received a current diagnosis of borderline epithelial ovarian tumor (formerly tumors of low malignant potential) * Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer that was treated only with surgery (example \[e.g.\], participants with Stage IA or Stage IB epithelial ovarian or fallopian tube cancers) * Have non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord stromal tumors) * Received prior radiotherapy to any portion of the abdominal cavity or pelvis * Received prior chemotherapy for any abdominal or pelvic tumor that include neoadjuvant chemotherapy (NACT) for ovarian, primary peritoneal or fallopian tube cancer * Received any biological and/or targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management and/or treatment of epithelial ovarian or peritoneal primary cancer * Have synchronous primary endometrial cancer * Have a prior history of primary endometrial cancer, except: Stage IA cancer; superficial myometrial invasion, without lymphovascular invasion; grade less than (\<) 3 or poorly differentiated subtypes, and this includes papillary serous, clear cell or other International Federation of Gynecological Oncologists (FIGO) Grade 3 lesions * With the exception of non-melanoma skin cancer and other specific malignancies as noted above, other invasive malignancies with any evidence of other cancers present within the last 5 years or previous cancer treatment that contraindicates this protocol therapy * Have a known hypersensitivity or allergy to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab formulations * Undergo major surgical procedure within 28 days prior to first bevacizumab dose, or anticipation of the need for a major surgical procedure during the course of the study except participants who receive NACT and will need interval surgery. This may include but is not limited to laparotomy. * Have prior allogeneic bone marrow transplantation or solid organ transplant * Have any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results * Have any approved or investigational anti-cancer therapy, including chemotherapy or hormonal therapy, with exceptions: Hormone-replacement therapy or oral contraceptives * Are administered treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intent * Have core biopsy or other minor surgical procedures within 7 days prior to the first dose of bevacizumab * Have known sensitivity to any component of bevacizumab * Have known sensitivity to any component of paclitaxel * Current treatment with anti-viral therapy for hepatitis B virus (HBV) * History of leptomeningeal disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population | From randomization until disease progression or death from any cause (up to approximately 55 months) | Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first. |
| PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation | From randomization until disease progression or death from any cause (up to approximately 55 months) | Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first. |
| Overall Survival - ITT Population | From randomization up to death from any cause (up to approximately 59 months) | Overall Survival (OS) is defined as the time from randomization to death from any cause. |
| Overall Survival - PD-L1-Positive Subpopulation | From randomization up to death from any cause (up to approximately 59 months) | Overall Survival (OS) is defined as the time from randomization to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. | Clinically-meaningful improvement defined as a \>=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31). |
| Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. | Clinically-meaningful improvement in patient-reported function and HRQoL during the treatment period, defined as a \>=10-point increase from the baseline score on each of the functional (social, emotional, physical, role) and GHS/QoLscales of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30). |
| Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. | Percentage of participants with clinical improvement, defined as \>= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30. |
| Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days. | Percentage of participants who remain stable defined as changes within 10 points from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30. |
| Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population | From randomization until disease progression or death from any cause (up to approximately 55 months) | OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery. |
| Percentage of Participants With at Least One Adverse Event | From randomization up to approximately 59 months | Percentage of participants with at least one adverse event. |
| Maximum Serum Concentration (Cmax) of Atezolizumab | Cycle 1 Day 1 post dose and Cycle 3 Day 1 post dose | — |
| Minimum Serum Concentration (Cmin) of Atezolizumab | Cycle 2 Day 1 predose, Cycle 3 Day 1 Predose, Cycle 4 Day 1 predose, Cycle 8 Day 1 predose, Cycle 16 Day 1 predose | — |
| Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab | Baseline to approximately 55 months | — |
| Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months). Cycle length=21 days. | Percentage of participants with deterioration in patient-reported function and HRQoL, defined as \>= 10 points decrease from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30. |
| Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population | From randomization until disease progression or death from any cause (up to approximately 55 months) | OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery. |
| Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population | From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months) | DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery. |
| Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population | From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months) | DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery. |
Countries
Australia, Austria, Belgium, Brazil, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Norway, Poland, Russia, South Korea, Spain, Sweden, Turkey (Türkiye), United States
Participant flow
Recruitment details
The study is considered Completed because all pre-planned study activities and analyses have been performed.
Participants by arm
| Arm | Count |
|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles. | 650 |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles. | 651 |
| Total | 1,301 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 289 | 272 |
| Overall Study | Lost to Follow-up | 9 | 10 |
| Overall Study | Physician Decision | 1 | 3 |
| Overall Study | Protocol Deviation | 1 | 4 |
| Overall Study | Study Terminated By Sponsor | 305 | 311 |
| Overall Study | Withdrawal by Subject | 45 | 51 |
Baseline characteristics
| Characteristic | Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Total | Placebo With Paclitaxel, Carboplatin and Bevacizumab |
|---|---|---|---|
| Age, Continuous | 58.9 Years STANDARD_DEVIATION 10.5 | 59.1 Years STANDARD_DEVIATION 10.6 | 59.3 Years STANDARD_DEVIATION 10.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 39 Participants | 77 Participants | 38 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 589 Participants | 1187 Participants | 598 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 23 Participants | 37 Participants | 14 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 5 Participants | 11 Participants | 6 Participants |
| Race (NIH/OMB) Asian | 150 Participants | 305 Participants | 155 Participants |
| Race (NIH/OMB) Black or African American | 8 Participants | 21 Participants | 13 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 22 Participants | 37 Participants | 15 Participants |
| Race (NIH/OMB) White | 464 Participants | 925 Participants | 461 Participants |
| Sex: Female, Male Female | 651 Participants | 1301 Participants | 650 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 272 / 651 | 289 / 650 |
| other Total, other adverse events | 637 / 642 | 637 / 644 |
| serious Total, serious adverse events | 304 / 642 | 215 / 644 |
Outcome results
Primary
Overall Survival - ITT Population
Overall Survival (OS) is defined as the time from randomization to death from any cause.
Time frame: From randomization up to death from any cause (up to approximately 59 months)
Population: Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Overall Survival - ITT Population | 46.59 Months |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Overall Survival - ITT Population | 50.53 Months |
Comparison: Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2), tumor PD-L1 status (IC0 vs. IC1/2/3), and treatment strategy (adjuvant vs. neoadjuvant).p-value: 0.343295% CI: [0.78, 1.09]Log Rank
Primary
Overall Survival - PD-L1-Positive Subpopulation
Overall Survival (OS) is defined as the time from randomization to death from any cause.
Time frame: From randomization up to death from any cause (up to approximately 59 months)
Population: PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Overall Survival - PD-L1-Positive Subpopulation | 49.15 Months |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Overall Survival - PD-L1-Positive Subpopulation | NA Months |
Comparison: Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2) and treatment strategy (adjuvant vs. neoadjuvant).p-value: 0.131695% CI: [0.66, 1.06]Log Rank
Primary
PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation
Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Time frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
Population: PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation | 18.50 Months |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation | 20.83 Months |
p-value: 0.037695% CI: [0.65, 0.99]Log Rank
Primary
Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Time frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
Population: Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population | 18.37 Months |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population | 19.48 Months |
p-value: 0.278595% CI: [0.79, 1.07]Log Rank
Secondary
Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population
DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Time frame: From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)
Population: Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population | 14.06 Months |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population | 16.59 Months |
Secondary
Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population
DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Time frame: From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)
Population: Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The PD-L1-positive subpopulation (defined as patients in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization) who underwent primary tumor-reductive surgery.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population | 13.44 Months |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population | 17.71 Months |
Secondary
Maximum Serum Concentration (Cmax) of Atezolizumab
Time frame: Cycle 1 Day 1 post dose and Cycle 3 Day 1 post dose
Population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Maximum Serum Concentration (Cmax) of Atezolizumab | Cycle 1 Day 1 | 487 µg/mL | Standard Deviation 163 |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Maximum Serum Concentration (Cmax) of Atezolizumab | Cycle 3 Day 1 | 614 µg/mL | Standard Deviation 209 |
Secondary
Minimum Serum Concentration (Cmin) of Atezolizumab
Time frame: Cycle 2 Day 1 predose, Cycle 3 Day 1 Predose, Cycle 4 Day 1 predose, Cycle 8 Day 1 predose, Cycle 16 Day 1 predose
Population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Minimum Serum Concentration (Cmin) of Atezolizumab | Cycle 16 Day 1 | 286 µg/mL | Standard Deviation 111 |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Minimum Serum Concentration (Cmin) of Atezolizumab | Cycle 2 Day 1 | 88.9 µg/mL | Standard Deviation 35.8 |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Minimum Serum Concentration (Cmin) of Atezolizumab | Cycle 3 Day 1 | 146 µg/mL | Standard Deviation 93 |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Minimum Serum Concentration (Cmin) of Atezolizumab | Cycle 4 Day 1 | 149 µg/mL | Standard Deviation 88.1 |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Minimum Serum Concentration (Cmin) of Atezolizumab | Cycle 8 Day 1 | 242 µg/mL | Standard Deviation 96.3 |
Secondary
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group
Clinically-meaningful improvement defined as a \>=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.
Population: Neoadjuvant Group. PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Presurgical/Surgery | 62.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 12 Day 1 | 63.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 4 Day 1 | 65.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 3 Months | 58.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 6 Day 1 | 71.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 4 Day 1 | 36.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 8 Day 1 | 71.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 6 Months | 61.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 12 Day 1 | 68.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 16 Day 1 | 63.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 16 Day 1 | 66.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 9 Months | 60.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 20 Day 1 | 66.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 8 Day 1 | 64.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Completion of Treatment/ Early Termination Visit | 62.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 12 Months | 70.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 3 Months | 57.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 20 Day 1 | 68.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 6 Months | 59.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 18 Months | 100 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 9 Months | 67.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 6 Day 1 | 55.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 12 Months | 47.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 18 Months | 66.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Completion of Treatment/Early Termination Visit | 51.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Presurgical/Surgery | 54.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Presurgical/Surgery | 50.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 4 Day 1 | 32.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 6 Day 1 | 48.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 8 Day 1 | 54.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 12 Day 1 | 57.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 16 Day 1 | 58.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Cycle 20 Day 1 | 48.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Completion of Treatment/Early Termination Visit | 51.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 3 Months | 51.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 6 Months | 51.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 9 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 12 Months | 58.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Abdominal Pain, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Presurgical/Surgery | 54.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 4 Day 1 | 59.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 6 Day 1 | 66.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 8 Day 1 | 63.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 12 Day 1 | 63.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 16 Day 1 | 64.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Cycle 20 Day 1 | 56.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Completion of Treatment/ Early Termination Visit | 58.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 3 Months | 53.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 6 Months | 62.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 9 Months | 63.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 12 Months | 62.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group | Bloating, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
Secondary
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group
Clinically-meaningful improvement in patient-reported function and HRQoL during the treatment period, defined as a \>=10-point increase from the baseline score on each of the functional (social, emotional, physical, role) and GHS/QoLscales of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30).
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.
Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Completion of Treatment/Early Termination Visit | 33.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Presurgical/Surgery | 35.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 4 Day 1 | 28.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 6 Day 1 | 35.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 8 Day 1 | 37.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 12 Day 1 | 45.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 16 Day 1 | 42.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 20 Day 1 | 41.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Completion of Treatment/Early Termination Visit | 38.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 37.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 40.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 32.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 23.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 33.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Presurgical/Surgery | 48.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 4 Day 1 | 38.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 6 Day 1 | 45.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 8 Day 1 | 50.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 12 Day 1 | 55.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 16 Day 1 | 53.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 20 Day 1 | 56.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 46.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 3 Months | 49.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 6 Months | 51.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 9 Months | 53.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 12 Months | 23.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Presurgical/Surgery | 32.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 4 Day 1 | 31.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 6 Day 1 | 36.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 8 Day 1 | 40.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 12 Day 1 | 39.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 16 Day 1 | 40.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 20 Day 1 | 45.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Completion of Treatment/Early Termination | 40.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 3 Months | 42.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 6 Months | 46.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 9 Months | 46.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 12 Months | 29.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 18 Months | 66.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Presurgical/Surgery | 31.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 4 Day 1 | 31.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 6 Day 1 | 42.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 8 Day 1 | 39.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 12 Day 1 | 41.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 16 Day 1 | 44.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 20 Day 1 | 44.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 3 months | 35.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 6 months | 30.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 9 months | 39.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 12 months | 29.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 18 months | 16.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 24 months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, PresurgicalSurgery | 44.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 4 Day 1 | 43.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 6 Day 1 | 51.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 8 Day 1 | 55.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 12 Day 1 | 60.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 16 Day 1 | 53.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 20 Day 1 | 59.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Completion of Treatment/ Early Termination Visit | 46.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 3 Months | 53.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 6 Months | 48.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 9 Months | 39.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 12 Months | 17.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 18 Months | 16.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 20 Day 1 | 43.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 16 Day 1 | 58.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Presurgical/Surgery | 33.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Completion of Treatment/Early Termination | 41.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 4 Day 1 | 18.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 12 months | 29.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 6 Day 1 | 25.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 3 Months | 44.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 8 Day 1 | 36.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 12 Day 1 | 43.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 6 Months | 35.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 16 Day 1 | 42.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 18 months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Cycle 20 Day 1 | 31.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 9 Months | 47.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Completion of Treatment/Early Termination Visit | 34.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 20 Day 1 | 61.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 39.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 12 Months | 54.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 39.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 24 months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 18 Months | 75.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 37.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 9 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, PresurgicalSurgery | 46.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Presurgical/Surgery | 40.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Presurgical/Surgery | 30.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 4 Day 1 | 22.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Completion of Treatment/ Early Termination Visit | 53.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 6 Day 1 | 33.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 4 Day 1 | 35.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 8 Day 1 | 39.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 4 Day 1 | 37.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 12 Day 1 | 47.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 6 Day 1 | 38.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 16 Day 1 | 46.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Cycle 20 Day 1 | 52.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 8 Day 1 | 44.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 39.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 6 Day 1 | 47.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 3 Months | 40.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 12 Day 1 | 41.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 6 Months | 48.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 3 Months | 53.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 9 Months | 52.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 16 Day 1 | 42.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 12 Months | 54.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 8 Day 1 | 59.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Cycle 20 Day 1 | 32.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Role Functioning, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Completion of Treatment/Early Termination Visit | 33.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Presurgical/Surgery | 33.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 12 Months | 41.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 4 Day 1 | 25.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 3 months | 33.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 6 Day 1 | 33.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Cycle 12 Day 1 | 61.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 8 Day 1 | 39.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 6 months | 33.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 12 Day 1 | 44.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | GHS/HRQoL, Post-Treatment Follow Up 6 Months | 41.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Social Functioning, Cycle 16 Day 1 | 44.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group | Emotional Functioning, Post-Treatment Follow Up 9 months | 34.2 Percentage of participants |
Comparison: Emotional Functioning, Presurgical/Surgeryp-value: 0.909695% CI: [0.58, 1.62]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 4 Day 1p-value: 0.466295% CI: [0.73, 2.01]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 6 Day 1p-value: 0.523795% CI: [0.51, 1.4]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 8 Day 1p-value: 0.382695% CI: [0.76, 2.07]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 12 Day 1p-value: 0.989395% CI: [0.56, 1.76]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 16 Day 1p-value: 0.689295% CI: [0.49, 1.61]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 20 Day 1p-value: 0.132495% CI: [0.3, 1.17]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Completion of Treatment/Early Termination Visitp-value: 0.917695% CI: [0.62, 1.7]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.786195% CI: [0.5, 1.68]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.453995% CI: [0.65, 2.65]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.484995% CI: [0.27, 1.86]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.74795% CI: [0.19, 3.34]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.089695% CI: [-44.86, 100]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 24 Months95% CI: [-94.3, 100]
Comparison: Physical Functioning, Presurgical/Surgeryp-value: 0.734795% CI: [0.56, 1.5]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Cycle 4 Day 1p-value: 0.047995% CI: [0.32, 1]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Cycle 6 Day 1p-value: 0.071295% CI: [0.36, 1.05]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Cycle 8 Day 1p-value: 0.816895% CI: [0.56, 1.58]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Cycle 12 Day 1p-value: 0.641795% CI: [0.5, 1.52]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Cycle 16 Day 1p-value: 0.882195% CI: [0.53, 1.72]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Cycle 20 Day 1p-value: 0.215895% CI: [0.32, 1.3]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Completion of Treatment/Early Termination Visitp-value: 0.476295% CI: [0.51, 1.37]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.758595% CI: [0.61, 1.96]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.998595% CI: [0.52, 1.93]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.106795% CI: [0.85, 5.06]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.617195% CI: [0.36, 5.61]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.808495% CI: [0.08, 23.57]Cochran-Mantel-Haenszel
Comparison: Physical Functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.317395% CI: [-100, 94.3]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Presurgical/Surgeryp-value: 0.680295% CI: [0.69, 1.77]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 4 Day 1p-value: 0.34795% CI: [0.48, 1.29]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 6 Day 1p-value: 0.556495% CI: [0.53, 1.41]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 8 Day 1p-value: 0.595% CI: [0.72, 1.99]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 12 Day 1p-value: 0.977895% CI: [0.57, 1.78]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 16 Day 1p-value: 0.600595% CI: [0.65, 2.12]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 20 Day 1p-value: 0.9995% CI: [0.5, 2]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Completion of Treatment/Early Termination Visitp-value: 0.263495% CI: [0.81, 2.15]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 3 Monthsp-value: 0.96495% CI: [0.56, 1.74]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 6 Monthsp-value: 0.411795% CI: [0.4, 1.46]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 9 Monthsp-value: 0.350595% CI: [0.63, 3.62]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 12 Monthsp-value: 0.243995% CI: [0.55, 9.45]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 18 Monthsp-value: 0.157395% CI: [-44.86, 100]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 24 Months95% CI: [-94.3, 100]
Comparison: Role Functioning, Presurgical/Surgeryp-value: 0.18295% CI: [0.45, 1.16]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 4 Day 1p-value: 0.004695% CI: [0.28, 0.8]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 6 Day 1p-value: 0.036195% CI: [0.36, 0.97]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.479595% CI: [-69.28, 85.94]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 8 Day 1p-value: 0.084895% CI: [0.39, 1.06]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 12 Day 1p-value: 0.122495% CI: [0.37, 1.13]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 16 Day 1p-value: 0.312795% CI: [0.41, 1.33]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 20 Day 1p-value: 0.606595% CI: [0.42, 1.65]Cochran-Mantel-Haenszel
Comparison: Role functioning, Completion of Treatment/ Early Termination Visitp-value: 0.217395% CI: [0.45, 1.2]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.131695% CI: [0.35, 1.15]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.767895% CI: [0.46, 1.76]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.733195% CI: [0.34, 2.14]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.123595% CI: [0.73, 10.92]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 18 Months95% CI: [-84.09, 84.09]
Comparison: Role functioning, Post-Treatment Follow Up 24 Months95% CI: [-94.3, 100]
Comparison: Social functioning, Presurgical/Surgeryp-value: 0.786995% CI: [0.65, 1.78]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 4 Day 1p-value: 0.250295% CI: [0.43, 1.25]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 6 Day 1p-value: 0.506695% CI: [0.5, 1.41]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 8 Day 1p-value: 0.812495% CI: [0.56, 1.59]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 12 Day 1p-value: 0.465695% CI: [0.7, 2.17]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 16 Day 1p-value: 0.672595% CI: [0.62, 2.12]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 20 Day 1p-value: 0.57895% CI: [0.41, 1.64]Cochran-Mantel-Haenszel
Comparison: Social functioning, Completion of Treatment/Early Termination Visitp-value: 0.761195% CI: [0.66, 1.76]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.758895% CI: [0.62, 1.94]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.142895% CI: [0.3, 1.19]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.980295% CI: [0.41, 2.39]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.196795% CI: [0.63, 8.7]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 24 Months95% CI: [-94.3, 100]
Secondary
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Percentage of participants with clinical improvement, defined as \>= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.
Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 3 Day 1 | 42.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 34.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Completion of Treatment/ Early Termination Visit | 27.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 3 Months | 29.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 18 Months | 42.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 3 Day 1 | 22.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 5 Day 1 | 23.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 8 Day 1 | 28.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 12 Day 1 | 35.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 16 Day 1 | 32.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 20 Day 1 | 34.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Completion of Treatment/Early Termination Visit | 32.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 35.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 32.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 37.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 42.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 5 Day 1 | 42.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 8 Day 1 | 47.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 12 Day 1 | 50.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 16 Day 1 | 52.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 20 Day 1 | 53.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 48.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 3 Months | 54.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 6 Months | 55.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 9 Months | 57.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 12 Months | 60 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 18 Months | 50 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 24 Months | 50 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 3 Day 1 | 30.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 5 Day 1 | 32.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 8 Day 1 | 37.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 12 Day 1 | 42.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 16 Day 1 | 43.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 20 Day 1 | 45.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Completion of Treatment/ Early Termination Visit | 40.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 3 Months | 42.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 6 Months | 43.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 9 Months | 50.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 12 Months | 62.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 18 Months | 57.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 3 Day 1 | 29.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 5 Day 1 | 30.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 8 Day 1 | 32.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 12 Day 1 | 34.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 16 Day 1 | 31.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 20 Day 1 | 35.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 6 Months | 30.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 9 Months | 38.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 12 Months | 44.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 18 Months | 42.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 3 Day 1 | 32.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 5 Day 1 | 33.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 8 Day 1 | 39.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 12 Day 1 | 41.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 16 Day 1 | 42.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 20 Day 1 | 42.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Completion of Treatment/ Early Termination Visit | 38.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 3 Months | 40.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 6 Months | 39.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 9 Months | 39.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 12 Months | 40.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 12 Day 1 | 41.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 6 Months | 37.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 16 Day 1 | 48.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Completion of Treatment/ Early Termination Visit | 28.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 12 Day 1 | 43.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 12 Months | 32.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 20 Day 1 | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 18 Months | 18.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 9 Months | 33.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 3 Day 1 | 19.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Completion of Treatment/ Early Termination Visit | 40.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 5 Day 1 | 21.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 3 Months | 38.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 8 Day 1 | 27.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 3 Months | 41.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 12 Day 1 | 32.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 12 Months | 34.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 16 Day 1 | 34.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 6 Months | 34.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 20 Day 1 | 32.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 16 Day 1 | 42.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Completion of Treatment/Early Termination Visit | 30.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 9 Months | 36.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 28.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 18 Months | 31.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 27.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 12 Months | 36.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 24.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 9 Months | 35.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 18.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 18 Months | 43.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 31.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 3 Day 1 | 40.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 5 Day 1 | 38.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 8 Day 1 | 45.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 20 Day 1 | 46.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 12 Day 1 | 50.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 3 Day 1 | 28.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 16 Day 1 | 50.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 3 Day 1 | 34.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 20 Day 1 | 51.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 5 Day 1 | 30.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 46.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 6 Months | 34.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 3 Months | 45.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 8 Day 1 | 33.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 6 Months | 43.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 5 Day 1 | 31.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 9 Months | 38.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 12 Day 1 | 36.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 12 Months | 27.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Completion of Treatment/ Early Termination Visit | 34.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 18 Months | 43.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 16 Day 1 | 35.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 8 Day 1 | 38.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 3 Day 1 | 31.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 20 Day 1 | 36.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 5 Day 1 | 32.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 3 Months | 27.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 8 Day 1 | 38.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 24 Months | 33.3 Percentage of participants |
Comparison: Emotional functioning, Cycle 3 Day 1p-value: 0.665195% CI: [0.7, 1.25]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 5 Day 1p-value: 0.992795% CI: [0.75, 1.34]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 8 Day 1p-value: 0.820995% CI: [0.77, 1.39]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 12 Day 1p-value: 0.650795% CI: [0.79, 1.45]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 16 Day 1p-value: 0.259695% CI: [0.87, 1.67]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 20 Day 1p-value: 0.653295% CI: [0.75, 1.58]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Completion Of Treatment/ Early Termination Visitp-value: 0.759295% CI: [0.76, 1.45]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.742495% CI: [0.62, 1.4]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.191295% CI: [0.85, 2.19]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.552695% CI: [0.45, 1.53]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.360995% CI: [0.32, 1.52]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.752795% CI: [0.2, 3.23]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 24 Months95% CI: [-100, 75.44]
Comparison: Physical functioning, Cycle 3 Day 1p-value: 0.317795% CI: [0.62, 1.17]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 5 Day 1p-value: 0.418495% CI: [0.63, 1.21]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 8 Day 1p-value: 0.57195% CI: [0.67, 1.24]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 12 Day 1p-value: 0.397395% CI: [0.65, 1.19]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 16 Day 1p-value: 0.516395% CI: [0.8, 1.55]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 20 Day 1p-value: 0.689795% CI: [0.64, 1.35]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Completion Of Treatment/ Early Termination Visitp-value: 0.573595% CI: [0.67, 1.25]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.141495% CI: [0.5, 1.1]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.865595% CI: [0.59, 1.55]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.301795% CI: [0.38, 1.35]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.232595% CI: [0.26, 1.39]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.171795% CI: [0.06, 1.69]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 24 Months95% CI: [-46.49, 79.82]
Comparison: Global health status/QoL, Cycle 3 Day 1p-value: 0.474595% CI: [0.84, 1.46]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 5 Day 1p-value: 0.549995% CI: [0.69, 1.22]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 8 Day 1p-value: 0.843695% CI: [0.73, 1.29]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 12 Day 1p-value: 0.579895% CI: [0.81, 1.46]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 16 Day 1p-value: 0.909495% CI: [0.74, 1.39]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 20 Day 1p-value: 0.400695% CI: [0.81, 1.67]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Completion of Treatment/ Early Termination Visitp-value: 0.402495% CI: [0.65, 1.19]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 3 Monthsp-value: 0.879695% CI: [0.67, 1.41]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 6 Monthsp-value: 0.43595% CI: [0.53, 1.32]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 9 Monthsp-value: 0.622595% CI: [0.47, 1.56]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 12 Monthsp-value: 0.577595% CI: [0.36, 1.77]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 18 Monthsp-value: 0.234395% CI: [0.07, 1.94]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 24 Monthsp-value: 0.083395% CI: [-100, 4.39]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 3 Day 1p-value: 0.601295% CI: [0.71, 1.21]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 5 Day 1p-value: 0.229195% CI: [0.65, 1.11]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 8 Day 1p-value: 0.657495% CI: [0.71, 1.24]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 12 Day 1p-value: 0.921795% CI: [0.76, 1.35]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 16 Day 1p-value: 0.769395% CI: [0.7, 1.3]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 20 Day 1p-value: 0.64795% CI: [0.64, 1.31]Cochran-Mantel-Haenszel
Comparison: Role functioning, Completion Of Treatment/ Early Termination Visitp-value: 0.639195% CI: [0.7, 1.25]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.089295% CI: [0.51, 1.05]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.05595% CI: [0.41, 1.01]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.016895% CI: [0.27, 0.88]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.002195% CI: [0.13, 0.65]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.781795% CI: [0.17, 3.8]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 24 Months95% CI: [-100, 75.44]
Comparison: Social functioning, Cycle 3 Day 1p-value: 0.664695% CI: [0.8, 1.41]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 5 Day 1p-value: 0.867795% CI: [0.73, 1.3]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 8 Day 1p-value: 0.76795% CI: [0.79, 1.38]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 12 Day 1p-value: 0.748795% CI: [0.71, 1.28]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 16 Day 1p-value: 0.188295% CI: [0.9, 1.68]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 20 Day 1p-value: 0.301595% CI: [0.84, 1.72]Cochran-Mantel-Haenszel
Comparison: Social functioning, Completion of Treatment/ Early Termination Visitp-value: 0.905995% CI: [0.73, 1.32]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.712595% CI: [0.65, 1.35]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.094795% CI: [0.43, 1.07]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.068695% CI: [0.32, 1.05]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.017595% CI: [0.17, 0.86]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.337695% CI: [0.09, 2.3]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.563795% CI: [-100, 23.34]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Percentage of participants who remain stable defined as changes within 10 points from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.
Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 35.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 12 Day 1 | 32.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 3 Months | 51.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 3 Day 1 | 53.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 5 Day 1 | 49.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 8 Day 1 | 47.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 12 Day 1 | 47.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 16 Day 1 | 50.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 20 Day 1 | 46.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Completion of Treatment/ Early Termination Visit | 46.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 41.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 42.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 46.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 44.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 100 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 3 Day 1 | 35.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 5 Day 1 | 30.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 8 Day 1 | 31.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 16 Day 1 | 27.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 20 Day 1 | 27.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 28.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 3 Months | 25.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 6 Months | 24.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 9 Months | 23.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 12 Months | 33.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 18 Months | 42.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 24 Months | 50 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 3 Day 1 | 40.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 5 Day 1 | 37.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 8 Day 1 | 40.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 12 Day 1 | 38.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 16 Day 1 | 36.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 20 Day 1 | 34.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Completion of Treatment/ Early Termination Visit | 31.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 3 Months | 30.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 6 Months | 33.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 9 Months | 27.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 12 Months | 28.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 18 Months | 28.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 3 Day 1 | 57.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 5 Day 1 | 52.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 8 Day 1 | 53.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 12 Day 1 | 53.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 16 Day 1 | 55.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 20 Day 1 | 49.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Completion of Treatment/ Early Termination Visit | 53.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 6 Months | 48.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 9 Months | 53.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 12 Months | 46.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 18 Months | 50.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 3 Day 1 | 43.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 5 Day 1 | 42.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 8 Day 1 | 39.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 12 Day 1 | 40.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 16 Day 1 | 38.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 20 Day 1 | 36.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Completion of Treatment/ Early Termination Visit | 37.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 3 Months | 38.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 6 Months | 39.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 9 Months | 39.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 12 Months | 42.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 18 Months | 35.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 8 Day 1 | 35.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 20 Day 1 | 52.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 5 Day 1 | 53.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Completion of Treatment/ Early Termination Visit | 51.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 12 Day 1 | 39.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 12 Months | 32.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 18 Months | 37.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 9 Months | 38.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 16 Day 1 | 33.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 3 Day 1 | 56.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 3 Months | 55.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 5 Day 1 | 50.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 20 Day 1 | 33.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 8 Day 1 | 49.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 8 Day 1 | 42.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 12 Day 1 | 51.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Completion of Treatment/ Early Termination Visit | 31.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 16 Day 1 | 48.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 6 Months | 47.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 20 Day 1 | 50.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 3 Months | 32.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Completion of Treatment/ Early Termination Visit | 44.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Completion of Treatment/ Early Termination Visit | 40.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 47.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 6 Months | 34.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 43.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 9 Months | 48.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 46.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 9 Months | 30.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 8 Day 1 | 30.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 56.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 12 Day 1 | 42.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 33.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 12 Months | 25.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 3 Day 1 | 30.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 12 Months | 43.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 5 Day 1 | 33.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 18 Months | 18.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 12 Day 1 | 32.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 6 Months | 42.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 16 Day 1 | 33.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 20 Day 1 | 34.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 18 Months | 37.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 28.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 3 Day 1 | 57.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 3 Months | 27.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 16 Day 1 | 43.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 6 Months | 29.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Post-Treatment Follow Up 3 Months | 38.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 9 Months | 34.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 8 Day 1 | 54.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 12 Months | 34.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 3 Day 1 | 42.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 18 Months | 25.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 12 Day 1 | 50.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 24 Months | 66.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 20 Day 1 | 42.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 3 Day 1 | 36.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 16 Day 1 | 51.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 5 Day 1 | 36.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL, Cycle 5 Day 1 | 44.8 Percentage of participants |
Comparison: Emotional Functioning, Cycle 3 Day 1p-value: 0.97795% CI: [0.76, 1.3]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 5 Day 1p-value: 0.731795% CI: [0.8, 1.37]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 8 Day 1p-value: 0.693795% CI: [0.8, 1.39]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 12 Day 1p-value: 0.391695% CI: [0.66, 1.18]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 16 Day 1p-value: 0.336395% CI: [0.63, 1.17]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Cycle 20 Day 1p-value: 0.676195% CI: [0.75, 1.55]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Completion of Treatment/ Early Termination Visitp-value: 0.699795% CI: [0.71, 1.26]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.359295% CI: [0.82, 1.72]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.879895% CI: [0.62, 1.51]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.385795% CI: [0.43, 1.39]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.685495% CI: [0.39, 1.85]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.453395% CI: [0.11, 2.7]Cochran-Mantel-Haenszel
Comparison: Emotional Functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.317395% CI: [-100, 75.44]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 3 Day 1p-value: 0.365895% CI: [0.87, 1.47]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 5 Day 1p-value: 0.761995% CI: [0.8, 1.36]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 8 Day 1p-value: 0.65895% CI: [0.81, 1.4]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 12 Day 1p-value: 0.272695% CI: [0.88, 1.57]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 16 Day 1p-value: 0.697395% CI: [0.69, 1.29]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 20 Day 1p-value: 0.44795% CI: [0.8, 1.64]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Completion of Treatment/ Early Termination Visitp-value: 0.51595% CI: [0.68, 1.21]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.210395% CI: [0.88, 1.82]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.796995% CI: [0.68, 1.66]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.8395% CI: [0.6, 1.91]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.698795% CI: [0.53, 2.55]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.144195% CI: [0.62, 17.77]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.317395% CI: [-100, 4.39]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Cycle 3 Day 1p-value: 0.759195% CI: [0.74, 1.25]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Cycle 5 Day 1p-value: 0.540395% CI: [0.83, 1.42]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Cycle 8 Day 1p-value: 0.265495% CI: [0.89, 1.55]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Cycle 12 Day 1p-value: 0.513895% CI: [0.82, 1.48]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Cycle 16 Day 1p-value: 0.213895% CI: [0.89, 1.67]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Cycle 20 Day 1p-value: 0.211495% CI: [0.88, 1.82]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Completion of Treatment/ Early Termination Visitp-value: 0.393895% CI: [0.85, 1.53]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Post-Treatment Follow Up 3 Monthsp-value: 0.779395% CI: [0.65, 1.38]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Post-Treatment Follow Up 6 Monthsp-value: 0.73795% CI: [0.69, 1.39]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Post-Treatment Follow Up 9 Monthsp-value: 0.965895% CI: [0.55, 1.79]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Post-Treatment Follow Up 12 Monthsp-value: 0.301595% CI: [0.29, 1.46]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Post-Treatment Follow Up 18 Monthsp-value: 0.753495% CI: [0.15, 3.94]Cochran-Mantel-Haenszel
Comparison: Global health status/ QoL, Post-Treatment Follow Up 24 Monthsp-value: 0.563795% CI: [-46.49, 79.82]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 3 Day 1p-value: 0.117795% CI: [0.61, 1.06]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 5 Day 1p-value: 0.27395% CI: [0.88, 1.56]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 8 Day 1p-value: 0.930695% CI: [0.73, 1.33]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 12 Day 1p-value: 0.863195% CI: [0.72, 1.32]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 16 Day 1p-value: 0.097795% CI: [0.95, 1.86]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 20 Day 1p-value: 0.072695% CI: [0.97, 2.1]Cochran-Mantel-Haenszel
Comparison: Role functioning, Completion of Treatment/ Early Termination Visitp-value: 0.997495% CI: [0.73, 1.38]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.706995% CI: [0.72, 1.63]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.306895% CI: [0.78, 2.16]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.137595% CI: [0.85, 3.16]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.95495% CI: [0.46, 2.29]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.428395% CI: [0.1, 2.64]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 24 Months95% CI: [-95.56, 100]
Comparison: Social Functioning, Cycle 3 Day 1p-value: 0.215395% CI: [0.64, 1.1]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Cycle 5 Day 1p-value: 0.787895% CI: [0.73, 1.27]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Cycle 8 Day 1p-value: 0.154495% CI: [0.61, 1.08]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Cycle 12 Day 1p-value: 0.801795% CI: [0.77, 1.4]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Cycle 16 Day 1p-value: 0.429595% CI: [0.63, 1.21]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Cycle 20 Day 1p-value: 0.95495% CI: [0.68, 1.44]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Completion of Treatment/ Early Termination Visitp-value: 0.749495% CI: [0.69, 1.3]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.641295% CI: [0.74, 1.62]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.865295% CI: [0.65, 1.67]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.691295% CI: [0.6, 2.18]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.583495% CI: [0.33, 1.86]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.957895% CI: [0.05, 16.05]Cochran-Mantel-Haenszel
Comparison: Social Functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.563795% CI: [-46.49, 79.82]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Time frame: Baseline to approximately 55 months
Population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab | Baseline evaluable participants | 0.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab | Post-baseline evaluable participants | 22.7 Percentage of participants |
Secondary
Percentage of Participants With at Least One Adverse Event
Percentage of participants with at least one adverse event.
Time frame: From randomization up to approximately 59 months
Population: Safety-evaluable population is defined as patients who received any amount of any study treatment (atezolizumab, placebo, paclitaxel, carboplatin, or bevacizumab).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With at Least One Adverse Event | 99.8 Percentage |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With at Least One Adverse Event | 100 Percentage |
Secondary
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Percentage of participants with deterioration in patient-reported function and HRQoL, defined as \>= 10 points decrease from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time frame: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months). Cycle length=21 days.
Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 8 Day 1 | 21.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 12 Day 1 | 18.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 24.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 16 Day 1 | 19.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 3 Day 1 | 21.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Completion of Treatment/ Early Termination Visit | 27.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 19.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 3 Months | 26.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 9 Months | 19.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 6 Months | 23.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 17.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 12 Months | 8.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 3 Day 1 | 24.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 18 Months | 14.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 21.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 5 Day 1 | 27.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 3 Day 1 | 12.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 8 Day 1 | 21.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 5 Day 1 | 17.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 5 Day 1 | 26.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 8 Day 1 | 14.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 8 Day 1 | 23.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 16 Day 1 | 13.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 20 Day 1 | 20.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 20 Day 1 | 15.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 12 Day 1 | 16.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Completion of Treatment/ Early Termination Visit | 19.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 12 Day 1 | 17.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 3 Months | 19.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 23.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 6 Months | 20.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 9 Months | 8.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 3 Months | 20.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 12 Months | 8.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 18 Months | 7.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 16 Day 1 | 17.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 6 Months | 20.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 3 Day 1 | 24.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 16 Day 1 | 20.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 5 Day 1 | 24.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 20 Day 1 | 18.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 8 Day 1 | 21.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 12 Months | 6.7 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 12 Day 1 | 17.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 9 Months | 22.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 16 Day 1 | 18.3 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 18 Months | 7.1 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 20 Day 1 | 20.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Completion of Treatment/ Early Termination Visit | 24.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Completion of Treatment/ Early Termination Visit | 20.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 3 Months | 20.5 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 6 Months | 20.9 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 12 Day 1 | 12.2 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 9 Months | 21.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 3 Day 1 | 29.0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 12 Months | 17.8 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 22.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 18 Months | 21.4 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 5 Day 1 | 29.6 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 24 Months | 0 Percentage of participants |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 20 Day 1 | 18.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 24 Months | 50.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 24 Months | 50 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 12 Day 1 | 16.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 20 Day 1 | 13.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 8 Day 1 | 25.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 20 Day 1 | 16.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 6 Months | 30.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 12 Day 1 | 13.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 12 Months | 22.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 20 Day 1 | 11.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 5 Day 1 | 28.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 8 Day 1 | 23.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 12 Day 1 | 16.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 16 Day 1 | 17.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 20 Day 1 | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Completion of Treatment/ Early Termination Visit | 25.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 3 Months | 23.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 6 Months | 25.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 9 Months | 25.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 12 Months | 25.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Post-Treatment Follow Up 18 Months | 25.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 3 Day 1 | 27.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 5 Day 1 | 27.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 8 Day 1 | 22.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Cycle 16 Day 1 | 15.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Completion of Treatment/ Early Termination Visit | 24.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 3 Months | 27.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 6 Months | 25.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 9 Months | 26.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 12 Months | 37.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 18 Months | 31.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Role Functioning, Post-Treatment Follow Up 24 Months | 16.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 3 Day 1 | 31.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 5 Day 1 | 30.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 12 Day 1 | 19.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Cycle 16 Day 1 | 17.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Completion of Treatment/ Early Termination Visit | 28.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 3 Months | 25.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 9 Months | 32.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 12 Months | 37.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 18 Months | 37.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Social Functioning, Post-Treatment Follow Up 24 Months | 33.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 3 Day 1 | 14.0 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 5 Day 1 | 15.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 8 Day 1 | 12.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 16 Day 1 | 12.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Cycle 20 Day 1 | 11.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Completion of Treatment/ Early Termination Visit | 19.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 3 Months | 16.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 6 Months | 14.6 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 9 Months | 18.4 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 18 Months | 31.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Emotional Functioning, Post-Treatment Follow Up 24 Months | 66.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 3 Day 1 | 22.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 5 Day 1 | 23.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 8 Day 1 | 18.1 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 12 Day 1 | 13.2 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Cycle 16 Day 1 | 13.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Completion of Treatment/ Early Termination Visit | 24.3 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 3 Months | 22.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 6 Months | 23.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 9 Months | 25.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 12 Months | 34.5 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | GHS/OoL Function, Post-Treatment Follow Up 18 Months | 43.8 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group | Physical Functioning, Cycle 3 Day 1 | 24.1 Percentage of participants |
Comparison: Social functioning, Cycle 3 Day 1p-value: 0.464795% CI: [0.84, 1.48]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 3 Day 1p-value: 0.606395% CI: [0.75, 1.63]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 5 Day 1p-value: 0.573995% CI: [0.63, 1.29]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 8 Day 1p-value: 0.379295% CI: [0.56, 1.25]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 12 Day 1p-value: 0.602295% CI: [0.73, 1.73]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 16 Day 1p-value: 0.789395% CI: [0.59, 1.49]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Cycle 20 Day 1p-value: 0.212595% CI: [0.42, 1.22]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Completion of Treatment/ Early Termination Visitp-value: 0.966195% CI: [0.7, 1.46]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.429995% CI: [0.52, 1.32]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.154295% CI: [0.36, 1.18]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.036395% CI: [1.04, 6.76]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.081495% CI: [0.85, 8.93]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.191595% CI: [0.43, 38]Cochran-Mantel-Haenszel
Comparison: Emotional functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.317395% CI: [-4.39, 100]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 3 Day 1p-value: 0.981895% CI: [0.73, 1.35]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 5 Day 1p-value: 0.626395% CI: [0.8, 1.45]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 8 Day 1p-value: 0.940795% CI: [0.73, 1.4]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 12 Day 1p-value: 0.7795% CI: [0.64, 1.39]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 16 Day 1p-value: 0.845895% CI: [0.63, 1.45]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Cycle 20 Day 1p-value: 0.702895% CI: [0.57, 1.46]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Completion of Treatment/ Early Termination Visitp-value: 0.139195% CI: [0.92, 1.83]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.800295% CI: [0.69, 1.62]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.975195% CI: [0.6, 1.68]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.381195% CI: [0.68, 2.78]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.39595% CI: [0.58, 3.9]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.899395% CI: [0.16, 5.12]Cochran-Mantel-Haenszel
Comparison: Physical functioning, Post-Treatment Follow Up 24 Monthsp-value: 0.317395% CI: [-23.34, 100]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 3 Day 1p-value: 0.598895% CI: [0.68, 1.25]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.217195% CI: [0.4, 34.56]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 24 Months95% CI: [-46.49, 79.82]
Comparison: Global health status/QoL, Cycle 5 Day 1p-value: 0.885995% CI: [0.72, 1.34]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 8 Day 1p-value: 0.253195% CI: [0.58, 1.16]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 12 Day 1p-value: 0.078595% CI: [0.46, 1.04]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 16 Day 1p-value: 0.064195% CI: [0.43, 1.03]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Cycle 20 Day 1p-value: 0.004695% CI: [0.29, 0.8]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Completion of Treatment/ Early Termination Visitp-value: 0.892895% CI: [0.7, 1.37]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 3 Monthsp-value: 0.610695% CI: [0.72, 1.74]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 6 Monthsp-value: 0.615995% CI: [0.67, 1.95]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 9 Monthsp-value: 0.537295% CI: [0.62, 2.49]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 12 Monthsp-value: 0.084595% CI: [0.89, 5.58]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 18 Monthsp-value: 0.134495% CI: [0.62, 21.56]Cochran-Mantel-Haenszel
Comparison: Global health status/QoL, Post-Treatment Follow Up 24 Monthsp-value: 0.317395% CI: [-23.34, 100]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 3 Day 1p-value: 0.02695% CI: [1.04, 1.92]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 5 Day 1p-value: 0.917995% CI: [0.75, 1.37]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 8 Day 1p-value: 0.58295% CI: [0.79, 1.53]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 12 Day 1p-value: 0.977295% CI: [0.67, 1.47]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 16 Day 1p-value: 0.1395% CI: [0.49, 1.1]Cochran-Mantel-Haenszel
Comparison: Role functioning, Cycle 20 Day 1p-value: 0.09995% CI: [0.4, 1.08]Cochran-Mantel-Haenszel
Comparison: Role functioning, Completion of Treatment/ Early Termination Visitp-value: 0.713395% CI: [0.76, 1.5]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.138495% CI: [0.9, 2.11]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.289595% CI: [0.78, 2.26]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.222195% CI: [0.77, 3.14]Cochran-Mantel-Haenszel
Comparison: Role functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.000595% CI: [2.08, 26.1]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 5 Day 1p-value: 0.767695% CI: [0.78, 1.4]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 8 Day 1p-value: 0.198395% CI: [0.89, 1.71]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 12 Day 1p-value: 0.987495% CI: [0.69, 1.44]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 16 Day 1p-value: 0.471695% CI: [0.58, 1.29]Cochran-Mantel-Haenszel
Comparison: Social functioning, Cycle 20 Day 1p-value: 0.204195% CI: [0.46, 1.18]Cochran-Mantel-Haenszel
Comparison: Social functioning, Completion of Treatment/ Early Termination Visitp-value: 0.777195% CI: [0.76, 1.45]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 3 Monthsp-value: 0.854295% CI: [0.64, 1.45]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 6 Monthsp-value: 0.12395% CI: [0.9, 2.5]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 9 Monthsp-value: 0.108995% CI: [0.88, 3.34]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 12 Monthsp-value: 0.001195% CI: [1.85, 18.3]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 18 Monthsp-value: 0.29595% CI: [0.43, 14.74]Cochran-Mantel-Haenszel
Comparison: Social functioning, Post-Treatment Follow Up 24 Months95% CI: [-37.72, 100]
Secondary
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population
OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Time frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
Population: Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the ITT population with measurable disease at baseline.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population | 88.7 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population | 92.8 Percentage of participants |
Secondary
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population
OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Time frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
Population: Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the PD-L1-Positive subpopulation with measurable disease at baseline.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population | 89.9 Percentage of participants |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population | 92.3 Percentage of participants |